NASDAQ · DNTH
Healthcare · Biotechnology
$82.25
Up+$0.45 (+0.55%)
Updated Nov 4, 2026, 12:06 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DNTH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
DNTH closed at $82.25 after 20 trading sessions, down 3.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $82.46 | $84.56 | $80.75 | $82.25 | 838.03K |
| Oct 30, 2026 | $81.29 | $83.73 | $80.575 | $82.38 | 496.89K |
| Oct 29, 2026 | $82.87 | $84.6959 | $81.875 | $82.70 | 849.06K |
| Oct 28, 2026 | $77.82 | $82.45 | $77.26 | $82.31 | 658.44K |
| Oct 27, 2026 | $79.55 | $81.10 | $78.64 | $79.52 | 748.69K |
| Oct 26, 2026 | $77.87 | $79.90 | $77.05 | $79.33 | 501.18K |
| Oct 23, 2026 | $76.03 | $78.155 | $76.02 | $76.78 | 379.23K |
| Oct 22, 2026 | $77.13 | $78.96 | $75.40 | $78.53 | 1.48M |
| Oct 21, 2026 | $78.89 | $80.7411 | $77.26 | $78.10 | 1.19M |
| Oct 20, 2026 | $74.61 | $79.93 | $73.165 | $78.75 | 1.87M |
| Oct 19, 2026 | $73.55 | $76.04 | $72.125 | $74.54 | 972.52K |
| Oct 16, 2026 | $74.41 | $75.3435 | $69.43 | $72.09 | 1.05M |
| Oct 15, 2026 | $75.77 | $77.55 | $72.67 | $74.53 | 943.58K |
| Oct 14, 2026 | $77.17 | $78.78 | $74.47 | $74.76 | 977.33K |
| Oct 13, 2026 | $81.42 | $81.46 | $77.25 | $77.58 | 1.32M |
| Oct 12, 2026 | $81.77 | $83.765 | $80.91 | $81.57 | 853.95K |
| Oct 9, 2026 | $82.36 | $85.20 | $82.13 | $82.37 | 738.87K |
| Oct 8, 2026 | $84.73 | $84.85 | $81.06 | $82.43 | 1M |
| Oct 7, 2026 | $84.60 | $86.61 | $84.13 | $84.88 | 562.47K |
| Oct 6, 2026 | $88.58 | $88.58 | $83.185 | $85.40 | 1.35M |
The latest Smart Investors Daily articles mentioning DNTH.
Company
Market Activity
Research & News
DNTH research
Company profile and research snapshot.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | Roth Capital | Buy | — |
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 4, 2026 | Citigroup | Buy | — |
| Aug 6, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 27, 2026
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
Yahoo · Oct 20, 2026
Dianthus Therapeutics has delivered very strong multi year gains, which naturally raises a question for anyone looking at the stock today. Is the current share price still in line with what the balance sheet and book value support, or has sentiment moved ahead of the underlying equity base? Over the past three years the share price has risen by more than 5x, which puts real weight on whether the current valuation can still be grounded in the company’s book value. The business is in an...
Benzinga · Oct 15, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $158 price target.
Yahoo · Oct 13, 2026
Dianthus Therapeutics (NASDAQ:DNTH) has earned its first place on Fortune’s Best Workplaces in BioPharma list, highlighting its employee culture as the clinical-stage biotechnology company continues expanding its workforce. Key Investor TakeawaysDianthus Therapeutics (NASDAQ:DNTH) ranked among the top 30 small- and medium-sized US biotechnology and pharmaceutical companies on Fortune’s 2026 workplace list.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DNTH.
